Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

for the HABS-HD Study Team

doi:10.1002/alz.12647

Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

for the HABS-HD Study Team

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Introduction: Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods: Plasma biomarkers of amyloid beta (Aβ)_40, Aβ₄₂, total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results: Dyslipidemia was associated with elevated Aβ₄₀ (P =.01) and Aβ₄₂ (P =.001) while hypertension was associated with elevated Aβ₄₀ (P =.003), Aβ₄₂ (P <.001), and total tau (P =.002) levels. Diabetes was associated with higher Aβ₄₀ (P <.001), Aβ₄₂ (P <.001), total tau (P <.001), and NfL (P <.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ₄₀ (P <.001), Aβ₄₂ (P <.001), total tau (P <.001), and NfL (P <.001) levels. Mexican Americans had significantly lower Aβ₄₀ (P <.001) and higher total tau (P =.005) levels. Discussion: Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.

Original language	English
Pages (from-to)	36-43
Number of pages	8
Journal	Alzheimer's and Dementia
Volume	19
Issue number	1
DOIs	https://doi.org/10.1002/alz.12647
State	Published - Jan 2023

Keywords

Alzheimer's disease
Mexican Americans
health disparities
plasma biomarkers

Access to Document

10.1002/alz.12647

Cite this

@article{9ae52ac9c66c4ffcb96fab0ca71c7a7c,

title = "Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice",

abstract = "Introduction: Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods: Plasma biomarkers of amyloid beta (Aβ)40, Aβ42, total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results: Dyslipidemia was associated with elevated Aβ40 (P =.01) and Aβ42 (P =.001) while hypertension was associated with elevated Aβ40 (P =.003), Aβ42 (P <.001), and total tau (P =.002) levels. Diabetes was associated with higher Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Mexican Americans had significantly lower Aβ40 (P <.001) and higher total tau (P =.005) levels. Discussion: Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.",

keywords = "Alzheimer's disease, Mexican Americans, health disparities, plasma biomarkers",

author = "{for the HABS-HD Study Team} and O'Bryant, {Sid E.} and Melissa Petersen and James Hall and Johnson, {Leigh A.}",

note = "Funding Information: HABS‐HD Study Team: MPIs: Sid E. O'Bryant, Kristine Yaffe, Arthur Toga, Robert Rissman, and Leigh Johnson; and the HABS‐HD Investigators: Meredith Braskie, Kevin King, Matthew Borzage, James R. Hall, Melissa Petersen, Raymond Palmer, Robert Barber, Yonggang Shi, Fan Zhang, Rajesh Nandy, Roderick McColl, David Mason, Bradley Christian, Nicole Philips, and Stephanie Large. Research reported here was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers R01AG054073 and R01AG058533. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research team also thanks the local Fort Worth community and the participants of the HABS‐HD study. Publisher Copyright: {\textcopyright} 2022 the Alzheimer's Association.",

year = "2023",

month = jan,

doi = "10.1002/alz.12647",

language = "English",

volume = "19",

pages = "36--43",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers

T2 - Important considerations for clinical trials and practice

AU - for the HABS-HD Study Team

AU - O'Bryant, Sid E.

AU - Petersen, Melissa

AU - Hall, James

AU - Johnson, Leigh A.

N1 - Funding Information: HABS‐HD Study Team: MPIs: Sid E. O'Bryant, Kristine Yaffe, Arthur Toga, Robert Rissman, and Leigh Johnson; and the HABS‐HD Investigators: Meredith Braskie, Kevin King, Matthew Borzage, James R. Hall, Melissa Petersen, Raymond Palmer, Robert Barber, Yonggang Shi, Fan Zhang, Rajesh Nandy, Roderick McColl, David Mason, Bradley Christian, Nicole Philips, and Stephanie Large. Research reported here was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers R01AG054073 and R01AG058533. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research team also thanks the local Fort Worth community and the participants of the HABS‐HD study. Publisher Copyright: © 2022 the Alzheimer's Association.

PY - 2023/1

Y1 - 2023/1

N2 - Introduction: Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods: Plasma biomarkers of amyloid beta (Aβ)40, Aβ42, total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results: Dyslipidemia was associated with elevated Aβ40 (P =.01) and Aβ42 (P =.001) while hypertension was associated with elevated Aβ40 (P =.003), Aβ42 (P <.001), and total tau (P =.002) levels. Diabetes was associated with higher Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Mexican Americans had significantly lower Aβ40 (P <.001) and higher total tau (P =.005) levels. Discussion: Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.

AB - Introduction: Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods: Plasma biomarkers of amyloid beta (Aβ)40, Aβ42, total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results: Dyslipidemia was associated with elevated Aβ40 (P =.01) and Aβ42 (P =.001) while hypertension was associated with elevated Aβ40 (P =.003), Aβ42 (P <.001), and total tau (P =.002) levels. Diabetes was associated with higher Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Mexican Americans had significantly lower Aβ40 (P <.001) and higher total tau (P =.005) levels. Discussion: Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.

KW - Alzheimer's disease

KW - Mexican Americans

KW - health disparities

KW - plasma biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85125588840&partnerID=8YFLogxK

U2 - 10.1002/alz.12647

DO - 10.1002/alz.12647

M3 - Article

C2 - 35235702

AN - SCOPUS:85125588840

SN - 1552-5260

VL - 19

SP - 36

EP - 43

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 1

ER -

Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this